- Initial drilling has begun at Pioneer Resources Dome North group of prospects
- Drilling will be completed where spodumene (gemstone) has been mapped in outcrop
- Drilling in and around the spodumene outcrops will be undertaken during the September quarter with assay results in October 2019
Pioneer Resources has commenced the initial drilling program at its Dome North group of prospects where spodumene (gemstone) has been mapped in outcrop.
On July 17 Pioneer released rock chip results with target 1 consisting of seven rock chips returning between 1.40 and 1.99 per cent lithium oxide and target 2 consisting of 17 rock chips returning between 1.65 and 3.70 per cent lithium oxide.
There were two emerging targets with rock chips returning between 1.53 and 2.63 per cent lithium oxide.
The first hole drilled at target 2 was drilled in an easterly direction and encountered pegmatite down-dip of the outcrop.
Pegmatite was intersected from 175 metres downhole and continued to the end of the hole at 311 metres.
This intersection suggests that the pegmatite is dipping approximately parallel to the first drill hole and the apparent width is greatly exaggerated.
Two further holes have been drilled to the west and targeted the pegmatite intersected the first hole drill at target 2.
They were drilled from the opposite direction and are believed to have given a better indication of the true width of the pegmatite.
To date, pegmatites have been intersected between 33-54 metres, 107-115 metres, 122-151 metres and 180-188 metres.
Spodumene mineralisation is indicated in all of the pegmatites intersected so far and for drill intervals where Pioneer’s geologists have logged spodumene.
Dome North is located approximately 130 kilometres south of Kalgoorlie and 200 kilometres north of Esperance.
Pioneer’s geology team recently discovered pegmatites containing spodumene and additional targets have been identified between Dome North and the Sinclair Mine, 18 kilometres north of Dome North.
Drilling in and around the spodumene outcrops will be undertaken during the September quarter with assay results in October 2019.